Tuesday, 2 June 2026
RAS was the undruggable target for forty years. A pan-RAS inhibitor extending life in the hardest tumor is real progress — and still measured in months.
Armando Cuesta, MD · 1 min read
Metastatic pancreatic cancer has, for a generation, been where good drugs go to disappoint. Second-line options buy weeks. So a hazard ratio of 0.40 for death — a median overall survival of 15.2 months against chemotherapy’s 6.6 in the RAS-mutant population of RASolute 302 — deserves to be read twice. This is not a surrogate endpoint or a press-release teaser. It is overall survival, the outcome that cannot be argued with.
It also matters why. RAS was called undruggable for forty years; its surface is smooth, its grip on GTP relentless. The KRAS-G12C inhibitors cracked one door. A pan-RAS approach that translates into survival in the most treatment-resistant solid tumor is the strongest signal yet that the entire pathway — not one mutation — is now therapeutic territory.
Continue reading →